Skip to content
INTERNATIONAL · DAILY NEWS & INTELLIGENCEAbout
Frankly NewsIndependent Global News & Real-time Analysis.
EditionInternational
HomeHealth

Health01

Why don't weight-loss drugs like Ozempic and Wegovy work for everyone?

As demand for popular weight-loss drugs like Ozempic and Wegovy continues to surge, clinicians and patients are confronting a persistent question: why do t...

01HealthFN
Editorial illustration, not a photo of the event.

As demand for popular weight-loss drugs like Ozempic and Wegovy continues to surge, clinicians and patients are confronting a persistent question: why do these medications produce dramatic results for some individuals while yielding disappointing outcomes for others? Researchers are now investigating whether the body's innate energy-saving response, a metabolic mechanism honed through evolution to protect against starvation, may explain the disparity. When caloric intake drops, the body appears to compensate by slowing metabolism and conserving energy, potentially blunting the effects of appetite-suppressing medications in certain patients. Scientists caution that the phenomenon is not yet fully understood and likely interacts with genetic, hormonal and behavioral factors that vary widely between individuals.

The findings could have significant implications for the future of obesity treatment, an area where one-size-fits-all prescribing remains common despite widely divergent patient responses. If researchers can identify reliable biomarkers for the energy-saving response, physicians may eventually tailor drug regimens, dosages or combination therapies to individual metabolic profiles, improving outcomes for patients who currently see little benefit. Public health experts also note the stakes are considerable, given the cost of these medications and the growing number of people seeking treatment. While no diagnostic tool is yet available to predict who will respond well, the emerging research signals a shift toward more personalized approaches in the management of obesity and related metabolic conditions.

Independent reporting synthesized from primary wires and global correspondents.